Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology
No safety concerns were observed with EXG-5003 administration The data suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines The Company is...
Elixir Achieves 20 Consecutive Years of URAC PBM Accreditation
Elixirgen Therapeutics Enters Memorandum of Understanding with Hitachi Global Life Solutions for the Development of Micro GMP Suites for Cell Therapy Administration
BALTIMORE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its...
BALTIMORE, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its...
Treatment with EXG-34217 increased the telomere length of CD34+ cells by 1.24-fold ex vivoTelomere flow-FISH study suggests the potential emergence of a cell population with longer telomeres in vivoNo...
BALTIMORE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced an oral presentation of new data showing successful ex vivo telomere elongation with lead asset, EXG-34217 (autologous CD34+ hematopoietic stem cells that have been treated with EXG-001), at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, Louisiana.
BALTIMORE, March 7, 2022 /PRNewswire/ -- Elixirgen Therapeutics, Inc., a Baltimore-based platform biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, announced today that it has entered into an exclusive three-year research collaboration agreement with Taisho Pharmaceutical Co., Ltd.
BALTIMORE, May 25, 2021 /PRNewswire/ -- Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, today announced the dosing of the first and second participants in its COVID-19 vaccine Phase 1/2 Clinical Trial in Japan.